ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO663

Is Urinary KIM-1 a Predictor of EGFR Decline, Incident Cardiovascular Disease, and All Cause Mortality?

Session Information

Category: Diabetes

  • 502 Diabetes Mellitus and Obesity: Clinical


  • Eickhoff, Mie K., Steno Diabetes Center, Gentofte, Denmark
  • Von Scholten, Bernt Johan, Novo Nordisk A/S, Soborg, Denmark
  • Reinhard, Henrik, Steno Diabetes Center A/S, Gentofte, Denmark
  • Hansen, Tine, Steno Diabetes Center, Gentofte, Denmark
  • Persson, Frederik, Steno Diabetes Center, Gentofte, Denmark
  • Parving, Hans-Henrik, Rigshospitalet, Copenhagen, Denmark
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Gentofte, Denmark

Urinary levels of kidney injury molecule 1 (KIM-1) has shown to reflect tubular pathophysiology. We evaluated KIM-1 as a predictor of decline in estimated glomerular filtration rate (eGFR), incident cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D) and microalbuminuria without clinical coronary artery disease.


We performed a prospective study including 200 patients, all receiving multifactorial treatment. Urinary KIM-1 was measured at baseline and was available in 191 patients. Adjusted Cox models included sex, age, LDL cholesterol, smoking, HbA1c, creatinine, systolic blood pressure and urine albumin excretion rate (UAER).
A decline in eGFR of >30%, which has recently been suggested as a valid renal outcome, at any time point during follow-up was the predefined endpoint of CKD progression. Hazard ratios (HR) are provided per 1 SD increment of log-transformed values of the urinary biomarker.


Patients were (± SD) 59 ± 9 years old, eGFR 91.1 ± 18.3 ml/min/1.73m2 and UAER (IQR) 103 (39–230) mg/24-h. During a median 6.1 years follow-up, there were 40 incident CVD events and 26 deaths and a total of 42 patients reached the predefined CKD progression endpoint after 4.9 years (median).
Higher urinary KIM-1 was a predictor of eGFR decline, unadjusted HR (95% CI): 1.9 (1.2-2.8); p=0.003, and in the adjusted model HR 1.7 (1.0-2.7); p=0.034. For CVD events urinary KIM-1 was a determinant in the unadjusted model (HR 1.4 (1.0-2.1); p=0.04) but not in the adjusted model (HR 1.4 (1.0-2.1); p=0.08), and of all-cause mortality in unadjusted (HR 2.0 (1.2-3.2); p=0.008) and adjusted (HR 2.3 (1.2-4.1); p=0.008) models.


In patients with T2D and microalbuminuria receiving multifactorial treatment, urinary KIM-1 was independently associated with deterioration in renal function and all-cause mortality.